110 related articles for article (PubMed ID: 15320742)
1. Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseases.
McGuire JJ
Curr Pharm Des; 2004; 10(22):2769-78. PubMed ID: 15320742
[TBL] [Abstract][Full Text] [Related]
2. Proteinase-activated receptor-1 (PAR1) and PAR2 mediate relaxation of guinea pig internal anal sphincter.
Huang SC
Regul Pept; 2014 Feb; 189():46-50. PubMed ID: 24631471
[TBL] [Abstract][Full Text] [Related]
3. Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles.
McGuire JJ; Hollenberg MD; Andrade-Gordon P; Triggle CR
Br J Pharmacol; 2002 Jan; 135(1):155-69. PubMed ID: 11786491
[TBL] [Abstract][Full Text] [Related]
4. Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2.
McGuire JJ; Dai J; Andrade-Gordon P; Triggle CR; Hollenberg MD
J Pharmacol Exp Ther; 2002 Dec; 303(3):985-92. PubMed ID: 12438518
[TBL] [Abstract][Full Text] [Related]
5. Proteinase-activated receptor 2 activation modulates guinea-pig mesenteric lymphatic vessel pacemaker potential and contractile activity.
Chan AK; Vergnolle N; Hollenberg MD; von der Weid PY
J Physiol; 2004 Oct; 560(Pt 2):563-76. PubMed ID: 15331674
[TBL] [Abstract][Full Text] [Related]
6. Age-related changes to vascular protease-activated receptor 2 in metabolic syndrome: a relationship between oxidative stress, receptor expression, and endothelium-dependent vasodilation.
Maruyama K; Kagota S; McGuire JJ; Wakuda H; Yoshikawa N; Nakamura K; Shinozuka K
Can J Physiol Pharmacol; 2017 Apr; 95(4):356-364. PubMed ID: 28103056
[TBL] [Abstract][Full Text] [Related]
7. Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice.
Hughes KH; Wijekoon EP; Valcour JE; Chia EW; McGuire JJ
Can J Physiol Pharmacol; 2013 Apr; 91(4):295-305. PubMed ID: 23627841
[TBL] [Abstract][Full Text] [Related]
8. Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review.
Kagota S; Maruyama K; McGuire JJ
Biomed Res Int; 2016; 2016():3130496. PubMed ID: 27006943
[TBL] [Abstract][Full Text] [Related]
9. Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides.
Hollenberg MD; Saifeddine M; al-Ani B; Kawabata A
Can J Physiol Pharmacol; 1997 Jul; 75(7):832-41. PubMed ID: 9315351
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles for PAR1- and PAR2-mediated vasomotor modulation in human arterial and venous conduits.
Ballerio R; Brambilla M; Colnago D; Parolari A; Agrifoglio M; Camera M; Tremoli E; Mussoni L
J Thromb Haemost; 2007 Jan; 5(1):174-80. PubMed ID: 17059415
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery.
Matsumoto T; Ishida K; Taguchi K; Kobayashi T; Kamata K
Peptides; 2009 Sep; 30(9):1729-34. PubMed ID: 19540892
[TBL] [Abstract][Full Text] [Related]
12. Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes.
Roviezzo F; Bucci M; Brancaleone V; Di Lorenzo A; Geppetti P; Farneti S; Parente L; Lungarella G; Fiorucci S; Cirino G
Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2349-54. PubMed ID: 16141401
[TBL] [Abstract][Full Text] [Related]
13. Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries.
Hamilton JR; Moffatt JD; Frauman AG; Cocks TM
J Cardiovasc Pharmacol; 2001 Jul; 38(1):108-19. PubMed ID: 11444493
[TBL] [Abstract][Full Text] [Related]
14. Proteinase-activated receptor-2: physiological and pathophysiological roles.
Coelho AM; Ossovskaya V; Bunnett NW
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):61-72. PubMed ID: 15317291
[TBL] [Abstract][Full Text] [Related]
15. Proteinase-activated receptor 4 (PAR4): action of PAR4-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR1 and PAR2.
Hollenberg MD; Saifeddine M; Al-Ani B; Gui Y
Can J Physiol Pharmacol; 1999 Jun; 77(6):458-64. PubMed ID: 10537233
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists.
Hamilton JR; Frauman AG; Cocks TM
Circ Res; 2001 Jul; 89(1):92-8. PubMed ID: 11440983
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress.
El-Daly M; Pulakazhi Venu VK; Saifeddine M; Mihara K; Kang S; Fedak PWM; Alston LA; Hirota SA; Ding H; Triggle CR; Hollenberg MD
Vascul Pharmacol; 2018 Oct; 109():56-71. PubMed ID: 29908295
[TBL] [Abstract][Full Text] [Related]
18. Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).
Yau MK; Lim J; Liu L; Fairlie DP
Expert Opin Ther Pat; 2016; 26(4):471-83. PubMed ID: 26936077
[TBL] [Abstract][Full Text] [Related]
19. Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport.
Vergnolle N; Macnaughton WK; Al-Ani B; Saifeddine M; Wallace JL; Hollenberg MD
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7766-71. PubMed ID: 9636225
[TBL] [Abstract][Full Text] [Related]
20. Novel agonists and antagonists for human protease activated receptor 2.
Barry GD; Suen JY; Le GT; Cotterell A; Reid RC; Fairlie DP
J Med Chem; 2010 Oct; 53(20):7428-40. PubMed ID: 20873792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
